A dose-response study on fenoterol (Berotec) solution by inhalation in asthmatic children.
Fenoterol (Berotec) was administered by inhalation, using a Bennett nebulizer, to symptom-free asthmatic children aged 6-13 years. It was demonstrated in a double-blind, crossover trial in 6 children that the improvement in the forced expiratory volume produced by inhalation of a nebulised fenoterol solution was not a placebo effect. Fenoterol (0.1 mg) produced effective bronchodilatation but there was a significant logarithmic dose-response relationship over the dose range tested (0.1-0.8 mg cumulative). There was no effect of the drug on heart rate even with the 0.8 mg dose.
D000293:Adolescent; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D012996:Solutions
D000336:Aerosols; D004983:Ethanolamines; D012996:Solutions; D005280:Fenoterol